DOR BioPharma, Inc (AMEX:DOR) today provided the following updates on the development progress of its biodefense programs: -- DOR provided guidance that its academic development partner is on track to file an Investigational New Drug Application (“IND”) with the US FDA before the end of the summer to initiate a Phase I clinical trial of RiVax(TM), its ricin toxin vaccine candidate.
